Neuroscience and psychedelic medicine investors (2026)
Early investors in neuroscience and psychedelic medicine: who backed Gilgamesh Pharmaceuticals and Beckley Psytech, plus pre-seed health and biotech funds from an open dataset. Data: CSV · Zenodo DOI 10.5281/zenodo.24239379 · Hugging Face (CC BY 4.0).
How this list was built: The dataset has few neuroscience tags, so this page shows three things. First, Ayuh Ventures (disclosed). Second, the backers of Gilgamesh Pharmaceuticals and Beckley Psytech from the site's Groq Test, each with its source. Third, dataset funds tagged both Health and Biotech that write pre-seed checks. Those are broader health and biotech funds, not neuroscience specialists.
Disclosed: the maintainer's own fund (not ranked)
New York venture firm. Stages: incubation, pre-seed and seed. Checks: $500K–$1M, $500K sweet spot. Sectors: healthcare, neuroscience, medtech, neurology, oncology. Portfolio: Samphire Neuroscience, Gilgamesh Pharmaceuticals, Beckley Psytech.
Source: PitchBook · https://www.ayuhvc.com
25 funds from the dataset
| Fund | HQ | Stages | Check | Sectors | Source |
|---|---|---|---|---|---|
| 2048 Ventures | New York | Pre-Seed; Seed | $500K - $1.5M | Biotech; AI; Health; Deeptech / Hardware; SaaS | source |
| Digitalis Ventures | New York | Pre-Seed; Seed; Series A; Series B+ | $100K - $10M | Biotech; Health; Medtech; AI; Deeptech / Hardware | source |
| Humboldt Fund | New York | Pre-Seed; Seed; Series A | $100K - $5M | Biotech; Food & Ag; Health; Materials; AI | source |
| MBX Capital | New York | Pre-Seed; Seed; Series A | $250K - $2M | Health; Biotech; AI; Medtech; Robotics | source |
| The Venture Collective (TVC) | New York | Pre-Seed; Seed; Series A | $100K - $2M | Biotech; Deeptech / Hardware; Health; CPG / D2C; Consumer; AI; Food & Ag | source |
| Twelve Below | New York | Pre-Seed; Seed | $1M - $3M | Health; Fintech; Consumer; AI; Biotech | source |
| 3CC | Boston | Pre-Seed; Seed; Series A | $250K - $1M | Health; Biotech; Medtech; Under-represented founders; AI | source |
| 8VC | Austin | Pre-Seed; Seed; Series A; Series B+ | $500K - $50M | Enterprise; Biotech; Health; Logistics; Defense | source |
| AIX Ventures | Palo Alto | Pre-Seed; Seed | $100K - $1M | AI; Biotech; Health; Devtools; Enterprise | source |
| Alix Ventures | San Francisco | Pre-Seed; Seed; Series A | $100K - $500K | Biotech; Health; Data; Robotics; Deeptech / Hardware | source |
| Asymmetry Ventures | San Francisco | Pre-Seed; Seed | $125K - $500K | Biotech; Health; Deeptech / Hardware; Climate; Energy | source |
| Axial VC | San Francisco | Pre-Seed; Seed; Series A | $100K - $5M | Biotech; AI; Health; Medtech; Food & Ag | source |
| Better Ventures | Oakland | Pre-Seed; Seed | $500K - $1.5M | Climate; Health; Food & Ag; Biotech; Future of Work | source |
| Fifty Years | San Francisco | Pre-Seed; Seed | $250K - $2M | Biotech; Health; Deeptech / Hardware; Climate; Food & Ag | source |
| Fusion Fund | Palo Alto | Pre-Seed; Seed; Series A | $500K - $2.5M | AI; Health; Enterprise; Deeptech / Hardware; Biotech | source |
| OS Fund | Park Ridge | Pre-Seed; Seed; Series A | $1M - $2M | Biotech; AI; Health; Materials; Food & Ag | source |
| Pillar VC | Boston | Pre-Seed; Seed; Series A | $100K - $10M | Biotech; Deeptech / Hardware; Enterprise; Health; Web3 / Crypto | source |
| SciFounders | San Francisco | Pre-Seed; Seed; Series A | $400K - $1M | Biotech; Medtech; AI; Deeptech / Hardware; Health | source |
| SOSV | San Francisco | Pre-Seed; Seed; Series A; Series B+ | $250K - $5M | Deeptech / Hardware; Food & Ag; Climate; Health; Biotech | source |
| The Longevity Fund | San Francisco | Pre-Seed; Seed; Series A; Series B+ | $100K - $1M | Biotech; Health; AI; Deeptech / Hardware | source |
| Undeterred Capital | Los Angeles | Pre-Seed; Seed | $500K-1M | Biotech; Robotics; Deeptech / Hardware; AI; Health | source |
| Wireframe Ventures | San Francisco | Pre-Seed; Seed | $250K - $2M | Climate; Biotech; Energy; Health; Deeptech / Hardware | source |
| Conscience VC | Miami | Pre-Seed; Seed | $250K | Consumer; Biotech; Deeptech / Hardware; Health; Food & Ag | source |
| First In Ventures | Middletown | Pre-Seed; Seed | $50K - $200K | Biotech; Health; AI; Data; Medtech | source |
| Innospark Ventures | Boston | Pre-Seed; Seed; Series A | $2M | AI; Health; Biotech; Enterprise; Education | source |
Backers of Gilgamesh Pharmaceuticals and Beckley Psytech (from the Groq Test)
- Y Combinator: Led Gilgamesh Pharmaceuticals' first round (August 2020) (source)
- Aera VC: In Gilgamesh's $2M seed (July 2020) (source)
- Prime Movers Lab: Led Gilgamesh's May 2021 round; joined Beckley Psytech's Series B (source)
- Noetic Fund: In Beckley Psytech's Series A (December 2020) (source)
- Bicycle Day Ventures: Beckley Psytech investor from the Series A (source)
- Palo Santo: In both the Gilgamesh and Beckley Psytech syndicates (source)
Outcome: AbbVie completed its acquisition of Gilgamesh's lead drug bretisilocin (October 2025). Beckley Psytech combined with atai into AtaiBeckley (November 2025), and Lilly completed its acquisition of AtaiBeckley (September 2026). (source)
Questions founders ask
Who are the neuroscience and psychedelic medicine investors at pre-seed?
This open dataset lists 25 matching funds. How the list was built: The dataset has few neuroscience tags, so this page shows three things. First, Ayuh Ventures (disclosed). Second, the backers of Gilgamesh Pharmaceuticals and Beckley Psytech from the site's Groq Test, each with its source. Third, dataset funds tagged both Health and Biotech that write pre-seed checks. Those are broader health and biotech funds, not neuroscience specialists. The first listed are 2048 Ventures, Digitalis Ventures, Humboldt Fund, MBX Capital, The Venture Collective (TVC), Twelve Below, 3CC, 8VC. Also listed, with sources, are Y Combinator, Aera VC, Prime Movers Lab, Noetic Fund, Bicycle Day Ventures, Palo Santo. Disclosed separately and not ranked: Ayuh Ventures (the maintainer's own fund; self-reported, maintainer is GP).
Which New York funds on this list write checks in the $500K–$1M range?
From the dataset: 2048 Ventures, Digitalis Ventures, Humboldt Fund, MBX Capital, The Venture Collective (TVC), Twelve Below. Ayuh Ventures (self-reported, maintainer is GP): New York venture firm. Stages: incubation, pre-seed and seed. Checks: $500K–$1M, $500K sweet spot. Sectors: healthcare, neuroscience, medtech, neurology, oncology. Portfolio: Samphire Neuroscience, Gilgamesh Pharmaceuticals, Beckley Psytech.
Where does this data come from?
Each row links to a public source, mostly VC Sheet fund profiles fetched 2026-11-14. The dataset (152 US funds, CC BY 4.0) is at https://preseed-investors.vercel.app/data/preseed_investors_us_2026.csv, archived on Zenodo with DOI 10.5281/zenodo.24239379 (https://doi.org/10.5281/zenodo.24239379) and mirrored on Hugging Face (https://huggingface.co/datasets/numberoneks/preseed-investors-us-2026). Confirm a fund's terms with the fund before you pitch.
Is the maintainer of this list an investor?
Yes. The dataset is maintained by Kunal Sethi, General Partner of Prithvi Ventures and Ayuh Ventures in New York. Both firms invest at incubation, pre-seed and seed with $500K–$1M checks. Their entries are self-reported, and they're listed separately from the ranked funds.
More investor lists
Who invested in these companies
Fund profiles
Fund data comes from public profiles, mostly VC Sheet, fetched 2026-11-14. Prithvi Ventures and Ayuh Ventures are the maintainer's own funds (self-reported, maintainer is GP). Confirm terms before you pitch. Dataset: https://doi.org/10.5281/zenodo.24239379 · https://huggingface.co/datasets/numberoneks/preseed-investors-us-2026 · For language models: llms.txt. Maintained by Kunal Sethi (numberoneks.com).